Mitotic checkpoint maintains genomic integrity before mitosis. Numerous observations have suggested that mitotic abnormalities produce chromosomal instability and aneuploidy. In MPNST, complex karyotypes showing numerical and structural aberrations have been described. 'Checkpoint with forkhead-associated domain and ring finger' (CHFR) was recently identified as defining a new early mitotic checkpoint. We examined the expression of CHFR in 96 cases of MPNST by immunohistochemical and molecular methods. We found reduced (score, p3) expression of CHFR in 63 out of 96 (66%) cases of MPNST, and such alteration was significantly correlated with a high mitotic count, a high Ki-67-labeling index, and a poor prognosis. In addition, MPNST with normal karyotype showed a strong (score, ¼ 5) expression of CHFR. Our results support the assertion that CHFR functions as an inhibitor of tumor proliferation.
Malignant peripheral nerve sheath tumor (MPNST)
is an uncommon soft-tissue neoplasm with a poor prognosis, occurring sporadically or associated with neurofibromatosis type 1 (NF1). Most MPNSTs arise in association with the major nerve trunk. However, the histogenesis of MPNST remains unclear, especially in sporadic tumors.
In MPNST, complex karyotypes showing numerical and structural changes for virtually all chromosomes have been described. 1, 2 We also detected numerical and structural aberrations of chromosomes in our earlier series. 3 Most sporadic cancers also have chromosomal aberrations. However, the detailed molecular mechanisms contributing to such aberrations remain widely controversial. A molecular study of MPNST demonstrated frequent alterations of INK4A and P53; 4, 5 however, such a deficiency of the G1 checkpoint cannot really explain the reason for chromosomal aberration. In fact, a recent study demonstrated that targeted inactivation of the P53 gene does not lead to chromosomal aberration. 6 Mitotic checkpoint maintains genomic integrity before mitosis, and promotes G2 arrest on detection of DNA damage. Numerous observations have suggested that chromosomal instability is caused by mitotic abnormalities. 7, 8 Some loss in the function of mitotic checkpoint protein such as BUBR1 or MAD2 can cause aneuploidy. 9 Although impairment of the molecules involved in mitotic checkpoints may be important in tumorigenesis, alterations of already known mitotic checkpoint genes occur very rarely. 10, 11 'Checkpoint with forkhead-associated domain and ring finger' (CHFR) has recently been identified as defining a new early mitotic checkpoint that delays transition into the metaphase in response to mitotic stress. 12 Previous studies of various cancers have demonstrated quite frequent inactivation of CHFR. [13] [14] [15] [16] [17] These studies suggest that inactivation of CHFR represents one of the more common molecular defects of a mitotic checkpoint gene.
In the present study, we have examined the expression of CHFR at both the protein level and the mRNA level and we have compared the results with clinicopathological parameters and survival rates. To our knowledge, this is the first investigation of CHFR analysis in MPNST, as well as in soft-tissue sarcoma.
Materials and methods

Patients and Tissue Specimens
Paraffin-embedded tissues from consecutive series of 96 cases of MPNST were obtained from the collection of soft-tissue tumors at the Department of Anatomic Pathology, Pathological Sciences, Graduate School of Medical Sciences, Kyushu University, Japan between 1964 and 2004. A total of 65 tumors were primary tumors, whereas 31 were recurrent tumors at the time of diagnosis. All patients were surgically treated according to the same general approach. The clinicopathological data of the patients are summarized in Table 1 . Clinicopathological parameters were classified (eg tumor size, Z5 cm vs o5 cm) according to previously described criteria. [18] [19] [20] The ages of the patients ranged from 11 months to 86 years (mean, 43.3 years). In all, 40 patients were diagnosed as suffering from NF1 according to the National Institutes of Health (NIH) criteria. 21 In 42 patients, the tumors occurred in the extremities (thigh, 18; upper arm, 13; lower leg, 7; and forearm, 4), whereas, in 54 patients, the tumors were located in the trunk, head, or neck (chest wall, 7; neck, 7; spinal canal, 7; back, 6; abdominal wall, 6; buttock, 4; retroperitoneum, 4; thoracic cavity, 3; abdominal wall, 3; mediastinum, 2; axilla, 2; head, 2; and groin, 1). Staging was performed only in primary tumors according to the new American Joint Committee on Cancer (AJCC) staging system. 22 Tumor grading was not performed according to the French Federation of Cancer Centers grading system, because it has been shown to be of no prognostic value in case of MPNST. 23 Instead, tumors were graded according to the Pediatric Oncology Group Nonrhabdomyosarcoma Soft Tissue Sarcoma (PNRSTS) grading system 24 in line with that previously described. 25 Follow-up information was available in 58 out of the 65 primary tumor cases. Median follow-up time was 44 months (range, 1-291 months). Of the 96 cases, 10 were successfully karyotyped and eight cases revealed structural and numerical chromosomal aberrations (Table 2) . These 10 patients with MPNST had no previous history of chemotherapy or radiation. We also obtained 10 benign peripheral nerve sheath tumors (BPNSTs), including four sporadic neurofibromas, four neurofibromas arising in NF1 patients, and two neurilemomas, for the purpose of comparison.
Tissues were stained with hematoxylin and eosin for histological examination. Diagnosis in each of the cases was based on histopathological features (proliferation of spindle cells with indistinct cytoplasm margins and wavy nuclei, arranged in fascicles with alternating cellular and myxoid areas), immunohistochemical findings (reactivity for S-100 protein), or clinical evidence (arising in NF1 patients or occurring from a nerve or neurofibroma), as described by Weiss and Goldblum. In addition, snap-frozen samples from seven primary tumors, for which normal adjacent tissue was available, were obtained from the MPNST panel. All these samples were obtained during surgical procedures. We confirmed that they had not previously received any other forms of therapy.
Immunohistochemistry
Sections (4-mm thick) were deparaffinized and dehydrated through xylene and ethanol. After the endogenous peroxidase activity was blocked by methanol containing 0.3% hydrogen peroxidase for 30 min, the sections were microwaved in 0.01 mol/l citrate buffer with 0.01% Tween (pH 6.0) for 20 min for heat-based antigen retrieval. The slides were exposed to 10% nonimmunized rabbit serum in phosphate-buffered saline (PBS) for 10 min, and then the sections were incubated overnight at 41C with goat polyclonal antibody against CHFR (sc-13288, 1:50; Santa Cruz Biotechnology, CA, USA). The labeled antigen was detected by a HistoFine Kit (Nichirei Pharmaceutical, Tokyo, Japan) and visualized by the 3,3 0 -diaminobenzidine tetrahydrochloride as a chromogen, accompanied by counterstaining with hematoxylin. The serial paraffin sections were also immunostained with a Ki-67 mouse monoclonal antibody (M 7240, 1:100; Dako, Copenhagen, Denmark) using the same procedure as for the CHFR staining. In each experiment, sections were treated similarly with PBS instead of the primary antibody as negative controls. Intact staining of adjacent normal tissue such as skin tissue or vessels served as an internal positive control.
Because CHFR is a nuclear protein and is localized within the nucleus, 27 we focused on its nuclear expression. The nuclear expression of CHFR was assessed semiquantitatively, with the percentage and intensity of stained cells compared with the adjacent normal tissue. At least 1000 tumor cells were counted in each case. The percentage of CHFRpositive cells was graded from 0 to 2 (0 ¼ o10% of positive cells; 1 ¼ 10-49%; 2 ¼ Z50%). The overall intensity of staining was assessed as follows: 0, no staining; 1, weak staining; 2, moderate staining (equivalent to normal tissue); 3, strong staining. The final score was calculated by adding the scores for the percentage and the intensity. Tumors were evaluated as 'reduced' when the final score was r3 and as 'preserved' when the score was otherwise. In addition, when the score was 5, tumors were considered as demonstrating strong expression. The Ki-67-labeling index was estimated by counting the number of positive cells/1000 tumor cells. All the hematoxylin and eosin-stained slides and the immunohistochemical slides were evaluated independently by three observers (CK, YO, and MT), and the grading was evaluated without knowledge of the clinical outcome.
RNA Extraction and Reverse Transcription-Polymerase Chain Reaction
Total RNA was extracted with 1 ml of TRIzol reagent (Invitrogen, CA, USA) from snap-frozen tumor samples, from corresponding normal tissues, and from an osteosarcoma cell line (SAOS2) according to the manufacturer's instructions. Osteosarcoma cell line SAOS2, which expresses wild-type CHFR, 12 was used as a positive control. To avoid contamination as much as possible, we confirmed that the tumor or normal tissue was not contaminated in each of the samples, with reference to their concordant HE-stained slides. ,+3mar  14  46XX  25 78,X,del(X)(q22),+1,+2,+2,+2,+2,+3,+4,+5,+5,+6,+6,+6,+add(7)(p22) Â 4,+9,+9,+add(9)(p22),+del(9)(p22) Â 2,+10,+11,+add(11) (p15),+12,+12,+12,+13,+13,+13,+14,add(14)(q32) Â 2,À16,+17,+18,+19,add (20) 
76,-Y,add(X)(p11.2),+add(X)(p22.3),+del(1)(q21),+add(1)(p13), +add(1)(p13),+2,+2,+add(3)(q21) Â 2,+add(4)(p16) Â 2,+dup(5)(q31q35) Â 2,+7,+7,+8,+8,der(9)t(1;9)(p13;p11.2) Â 2,+add(9) (p11.2) Â 2,+10,+10,+11,add (12) (7) add (7)(p22)add(7)(q11.2) Â 2,+add(8)(p11.2),-9,der(9)add(9)(p24)add(9)(q11),der (11) Total RNA (5 mg) from each of the samples were reverse-transcribed using Superscript III reverse transcriptase (Invitrogen, CA, USA) in order to prepare first-strand cDNA. The reverse transcription-polymerase chain reaction (RT-PCR) was performed using primers and temperature profiles, as previously described (Table 3) . 13 Negative controls consisted of RNA which had been treated identically but without the addition of reverse transcriptase. The PCR products were electrophoresed on 2% agarose gel with ethidium bromide staining. Realtime PCR was carried out using ABsolutet QPCR SYBR Green Mixes (ABgene, Surrey, UK) in a solution containing 100 ng of cDNA, 25 ml of SYBR Green Mix, and 3.5 pmol of each of the primers. The primers used are summarized in Table 3 , and were as described previously. 16, 28 The PCR cycling protocol included one cycle at 951C for 10 min, followed by 40 cycles at 951C for 15 s and at 601C for 1 min. Fluorescent signals were detected using an ABI Prism 7700 (Applied Biosystems, CA, USA). Data were analyzed using ABI Prism 7700 SDS Software (also Applied Biosystems). Standard curves were generated using serial dilutions of Human Total RNA (BD Biosciences Clontech, NJ, USA). Ratios of the intensities of the CHFR and GAPDH signals were used as a relative measure of the expression level of CHFR mRNA in each specimen.
Statistics
The correlation between the immunohistochemical expression of CHFR and the clinicopathologic parameters was assessed by t-test, w 2 -square test, and Fisher's exact test. Association between CHFR mRNA expression and CHFR immunohistochemical expression status was examined using MannWhitney's U-test. The clinical outcomes of the MPNST patients were followed between surgery and the date of the last follow-up or the date of death by disease. Survival analysis was carried out only for those groups of patients with primary tumors, while patients who were alive or who had died of other causes were censored. Overall survival was estimated by the Kaplan-Meier method with the log-rank test. Multivariate analysis was performed using the Cox proportional hazards model with the stepwise method. A two-sided P-value of o0.05 was considered statistically significant. All tests were carried out in consultation with a biostatistician.
Results
Correlation between CHFR Immunohistochemical Expression and Clinicopathological Parameters CHFR immunoreactivity in the normal skin tissue is presented in Figure 1a . In normal tissue, CHFR expression was detected mainly in the nucleus (score ¼ 4) and partly in the cytoplasm, but no membranous staining was found.
The correlation between CHFR immunoreactivity and the clinicopathological parameters is presented in Table 4 . The nuclear expression was reduced in 63 of the 96 (66%) MPNST cases (Figure 1b) , whereas in the remaining 33 (34%) it was preserved (Figure 1c) . In contrast, all the BPNSTs showed preserved expression (Figure 1d ). Reduced expression of CHFR was significantly correlated with young age (P ¼ 0.0200), site of trunk, head or neck (P ¼ 0.0160), presentation in the recurrent tumor (P ¼ 0.0093), a high mitotic count (P ¼ 0.0023), and a high Ki-67-labeling index (P ¼ 0.0064). There was a trend toward a correlation between reduced CHFR expression and deep tumor location (P ¼ 0.0614); however, this finding was not statistically significant.
Focusing on the karyotyping data, two (20%) MPNST cases with normal karyotype showed a strong (score, Z5) expression, while eight (80%) with chromosomal aberration did not (score, r4, P ¼ 0.0222) ( Table 5) .
RT-PCR Analysis
CHFR mRNA levels were examined in seven normal tissue and in seven tumor tissue-paired MPNST samples. CHFR was expressed at detectable levels in Figure 2 ). SAOS2, an osteosarcoma cell line used as a positive control, also showed CHFR mRNA expression. However, the remaining three (43%) MPNST samples showed no, or only negligible, mRNA expression. The data with real-time PCR were matched with data obtained with RT-PCR, and were found to be significantly associated with the immunohistochemical data (P ¼ 0.0339) (Figure 3 ).
Univariate and Multivariate Analysis of Prognostic Parameters
The results of univariate and multivariate analysis of the prognostic factors for overall survival in 58 patients with primary tumors are shown in Table 6 . In the univariate analysis, poor prognosis was found to be significantly correlated with the presence of NF1 (P ¼ 0.0152), deep tumor situation (P ¼ 0.0311), tumor size of Z5 cm (P ¼ 0.0485), the presence of tumor necrosis (P ¼ 0.0266), Z20 mitoses per 10 HPF (P ¼ 0.0075), a Ki-67-labeling index of Z30% (P ¼ 0.0488), a PNRSTS grade of Z2 (P ¼ 0.0376), an AJCC stage of ZIII (P ¼ 0.0051), and reduced CHFR immunohistochemical expression (P ¼ 0.0072). An advanced age of more than 50 years demonstrated a trend toward a correlation with poor prognosis (P ¼ 0.0686), but this finding was not statistically significant. The immunohistochemical expression of CHFR and Kaplan-Meier survival estimates are shown in Figure 4 . Patients with reduced CHFR expression had a significantly worse prognosis than those with preserved expression. The prognostic parameters and CHFR immunohistochemical expression were also analyzed using multivariate analysis. In the multivariate analysis, AJCC stage 
Discussion
CHFR is expressesed ubiquitously in normal human tissue. 12 In this study, a reduced expression of CHFR protein was recognized only in malignant tumors. Both BPNSTs and normal tissue showed preserved expression. Although the sample size is small, we found that MPNST with normal karyotype showed a strong expression of CHFR. Chaturvedi et al 29 demonstrated in their preliminary studies that the expression of CHFR protein is cell cycle dependent. If the normal function of CHFR as a mitotic checkpoint protein is preserved, its expression increases in response to mitotic stress. Thus, it is suggested that the expression of CHFR may be activated and may increase in response to the high proliferative activity of the malignant tumor, when the normal function of CHFR is preserved. If we assume that a strong expression of CHFR reflects such an increase as a normal response, then we can explain the intact karyotype of MPNST which strongly expressed CHFR, on the grounds that MPNST with an intact karyotype may retain the normal function of CHFR, and the normal increase of CHFR may play a role in ensuring chromosomal stability.
We found a significant association between the reduced expression of CHFR and a high mitotic count. This finding was in agreement with a previous study reporting an association between the expression of CHFR and mitosis. 12 It is suggested that alteration of CHFR is involved in the mitotic checkpoint impairment. Another important point is that a high mitotic count means high proliferative activity; there is the possibility that a reduction of CHFR causes accelerated tumor cell proliferation. Furthermore, MPNST with a reduction of CHFR revealed a high Ki-67-labeling index. According to these two experimental results about proliferative activity, it is would seem that CHFR act as an inhibitor of tumor proliferation. Because CHFR defines a mitotic checkpoint, it is naturally assumed that CHFR inhibits tumor proliferation. In this study, multivariate survival analysis showed that the reduced expression of CHFR was an independent predictor of poor prognosis. Accordingly, it is thus possible to build up a hypothesis that CHFR is an inhibitor of tumor proliferation and that the alteration of CHFR results in chromosomal aberra- 
Trunk, head and neck (n ¼ 27) 31 and which is frequently upregulated in a variety of tumors. 32, 33 Overexpression of Aurora-A can cause aneuploidy. 34 Yu et al 30 also generated CHFR knockout mice and suggested that CHFR is a tumor suppressor that ensures chromosomal stability. Our experimental results agree with those obtained by them and support their conclusion.
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Tumor depth
The average age of the patients who had reduced CHFR expression was significantly lower than that of those who had preserved expression. It seems reasonable to suppose that inactivation of CHFR in MPNST is not age-related. Interestingly, some investigators have demonstrated that promoter hypermethylation of CHFR was age-related in normal colonic mucosa, but not age-related in lung tissue or gastric mucosa. 15, 16 Promoter hypermethylation is one of the major causes behind the inactivation of CHFR; epigenetic inactivation of CHFR has been detected at a variable rate in other tumors. [13] [14] [15] [16] [17] A study of methylation lies outside the scope of the persent paper, but it does warrant further investigation.
The reduced expression of CHFR was significantly more frequent in MPNST arising in the nonextremities. As mentioned above, CHFR turned out to be a tumor suppressor. It seems therefore reasonable to suppose that MPNSTs arising in the nonextremities and those arising in the extremities may develop via separate molecular pathways. A previous larger study showed a significant association between location in the nonextremities and poor prognosis, 35 although the statistical analysis in the current study omitted 'tumor site' from among the prognostic factors. As for other sarcomas, welldifferentiated lipoma-like liposarcoma has a different status of P53 and MDM2 immunohistochemical expression according to tumor site, and also has a different clinical outcome according to tumor site. 36 A difference in location sometimes leads to a difference in character for the same entity. In view of our results, there remains the possibility that MPNST is also divided into two different categories.
We also found that recurrent MPNST showed more a frequent reduction of CHFR. It may follow that the alteration of CHFR accumulates as the tumor progresses, or that the alteration of CHFR is an event which occurs late in the tumorigenesis of MPNST. Additionally, as is the case with MPNST arising in the non-extremities, experience tells us that recurrent MPNST also carries with it a poor prognosis. Thus, the above statistical results with regard to tumor site and recurrence may also have a close link to the fact that the reduced expression of CHFR was an independent predictor of poor prognosis.
Mitotic checkpoint dysfunction is associated with sensitivity to microtubule inhibitory chemotherapeutic drugs. Tumors with reduced CHFR expression may be more sensitive to microtubule inhibitors because of checkpoint failure. Although further studies are necessary, there is a possibility that the immunohistochemical expression of CHFR is a marker of responsiveness to microtubule inhibitors, such as paclitaxel.
In conclusion, we found altered expression of CHFR protein in 63 out of 96 (66%) cases of MPNST, and such alteration was significantly correlated with a high mitotic count, a high Ki-67-labeling index, and a poor prognosis. Our results support the assertion that CHFR functions as a tumor suppressor.
